medstrat_logo_500x128
January 17th, 2017 | News

Startups to Watch: SPR Therapeutics

SPR Therapeutics has developed a peripheral nerve stimulation therapy to address chronic pain syndromes in the back, limbs, and shoulder, as well as acute pain following joint replacement surgery. Delivered percutaneously for 30 days, the company’s FDA-cleared single-use disposable PNS …

nasdaq-apo
January 17th, 2017 | News

SPR Therapeutics Names Dave Youngberg Vice President of Sales

CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) — SPR® Therapeutics announced today that industry veteran, Dave Youngberg, has joined the neurostimulation company as Vice President of Sales. Youngberg brings extensive experience in neurostimulation sales, product launch, and commercialization of new therapies …

cnbc_logo
January 5th, 2017 | News

Tech devices to treat chronic pain could curb opioid use

In 2014 radio producer Coy Dean was at a promotional event in Greenville, North Carolina, when he had a stroke. The 48-year-old couldn't move the left side of his body, and even as he started to recover, his joints were …
vcnd2
December 9th, 2016 | News

Vapogenix Secures $8.2M in Series C

Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the company announced today. Pamoja Capital, prominent …

medstrat_logo_500x128
January 17th, 2017 | News

Startups to Watch: SPR Therapeutics

SPR Therapeutics has developed a peripheral nerve stimulation therapy to address chronic pain syndromes in the back, limbs, and shoulder, as well as acute pain following joint replacement surgery. Delivered percutaneously for 30 days, the company’s FDA-cleared single-use disposable PNS …

nasdaq-apo
January 17th, 2017 | News

SPR Therapeutics Names Dave Youngberg Vice President of Sales

CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) — SPR® Therapeutics announced today that industry veteran, Dave Youngberg, has joined the neurostimulation company as Vice President of Sales. Youngberg brings extensive experience in neurostimulation sales, product launch, and commercialization of new therapies …

cnbc_logo
January 5th, 2017 | News

Tech devices to treat chronic pain could curb opioid use

In 2014 radio producer Coy Dean was at a promotional event in Greenville, North Carolina, when he had a stroke. The 48-year-old couldn't move the left side of his body, and even as he started to recover, his joints were …
vcnd2
December 9th, 2016 | News

Vapogenix Secures $8.2M in Series C

Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the company announced today. Pamoja Capital, prominent …